Abdominal myomectomy.........................................................23 |
Adnexal lesion...........................................................................165 |
Adnexal preservation................................................................165 |
Androgenization........................................................................255 |
Anovulation................................................................................255 |
Anti-mullerian hormone.............................................................65 |
Anxiety........................................................................................142 |
Assessment................................................................................170 |
Assisted reproductive technology.............................................55 |
Attitudes.....................................................................................138 |
Bem Sex Role Inventory...........................................................138 |
Beta-human chorionic gonadotrophin.....................................97 |
Biopsy.........................................................................................117 |
Bipolar cord coagulation............................................................79 |
Bladder pain..............................................................................117 |
Bleeding.....................................................................................123 |
Body mass index.........................................................................89 |
Borderline ovarian tumors.......................................................224 |
C1q/tumor necrosis factor-related protein-5 ..............................89 |
Cadaveric...................................................................................243 |
Carcinosarcoma........................................................................154 |
Central nervous system............................................................170 |
Cervical cerclage......................................................................272 |
Climacteric.................................................................................178 |
Clinical characteristics.............................................................133 |
Cognitive behavioral therapy...................................................178 |
Congenital abnormalities.........................................................170 |
Cortisol.......................................................................................218 |
Cystoscopy.................................................................................117 |
Cytoreduction..............................................................................62 |
Cytoreductive surgery.................................................................31 |
Darbepoietin................................................................................41 |
Deeply infiltrating endometriosis............................................133 |
Dental health.............................................................................264 |
Developing world......................................................................106 |
Dissection...................................................................................243 |
Donor programme....................................................................236 |
Donors........................................................................................236 |
Double-balloon catheter..........................................................231 |
Education...................................................................................243 |
Endometriosis......................................................................41, 133 |
Environmental...........................................................................255 |
Enzian classification.................................................................133 |
Erythropoietin..............................................................................41 |
Ethics..........................................................................................236 |
Female students........................................................................138 |
Fertility preservation.................................................................196 |
Fibroid............................................................................15, 55, 211 |
First trimester...............................................................................37 |
First trimester screening.............................................................97 |
Free-androgen index..................................................................89 |
Gender-role orientation............................................................138 |
Genetic factors..........................................................................255 |
Gestational hypertension.........................................................106 |
Granulosa cell ovarian tumor..................................................247 |
Gynecologic...............................................................................123 |
Hemostasis..................................................................................23 |
Hemostatic tourniquet...............................................................23 |
HIPEC.........................................................................................213 |
Huge myoma.............................................................................211 |
Hydrodistension........................................................................117 |
Hyperandrogenism...................................................................255 |
Hypogastric................................................................................123 |
Hysterectomy.......................................................................15, 165 |
In vitro fertilization................................................................55, 97 |
Infertility.....................................................................................255 |
Infertility treatment.....................................................................84 |
Insulin resistance........................................................................89 |
Interstitial laser............................................................................79 |
Interval.......................................................................................272 |
Intracytoplasmic sperm injection.............................................97 |
Intrauterine insemination............................................................1 |
Iodine deficiency.........................................................................37 |
Intrauterine death.....................................................................147 |
Labor induction.........................................................................231 |
Laparoscopy..............................................................................272 |
Leiomyoma..................................................................................55 |
Leiomyosarcoma......................................................................154 |
Leptin.........................................................................................218 |
Liver..............................................................................................62 |
Malignant degeneration.............................................................84 |
Management..............................................................................213 |
Mature cystic teratoma...............................................................84 |
Menopause................................................................................178 |
Menstruation..............................................................................138 |
Meta-learning...............................................................................70 |
MIRCERA......................................................................................41 |
Minimally invasive.........................................................................8 |
Misoprostol..................................................................................23 |
Monochorionic............................................................................79 |
mTOR.........................................................................................247 |
national program.......................................................................196 |
Neoadjuvant chemotherapy......................................................31 |
Neonatal death............................................................................70 |
Neurosurgical procedure.........................................................170 |
Nuchal translucency...................................................................97 |
Occupational.............................................................................255 |
Oncofertility...............................................................................196 |
Oocyte donation........................................................................236 |
Oocyte-embryo freezing..........................................................196 |
Oral care....................................................................................264 |
Ovarian cancer..............................................................47, 62, 247 |
Ovarian capacity.........................................................................65 |
Ovarian carcinoma...................................................................213 |
Pelvic..........................................................................................123 |
Pelvis...........................................................................................243 |
Perinatal outcomes...................................................................147 |
Perioperative outcomes...............................................................8 |
Phenotyping...............................................................................117 |
Polycystic ovary syndrome.......................................................255 |
Polycystic ovary syndrome.........................................................89 |
Pont hepatique............................................................................62 |
Postoperative.............................................................................142 |
Postpartum.................................................................................123 |
Pregnancy......................................................................37, 97, 264 |
Pregnancy complications.........................................................218 |
Pregnancy outcomes................................................................147 |
Pregnancy rate...............................................................................1 |
Pregnancy-associated plasma protein-A..................................97 |
Prenatal diagnosis.....................................................................170 |
Preoperative...............................................................................142 |
Preterm birth...............................................................................70 |
Primary prevention.....................................................................47 |
Primary surgery...........................................................................31 |
Prognosis............................................................................154, 213 |
Radiofrequency ablation............................................................79 |
Rapamycin.................................................................................247 |
Rat.................................................................................................65 |
Rational drug treatment.............................................................65 |
Re-operation..............................................................................165 |
Receptor activator.......................................................................41 |
ReCoDe intrauterine fetal demise...........................................106 |
Recurrence................................................................................213 |
Relapse.......................................................................................213 |
Residual.....................................................................................213 |
Risk factors..................................................................................15 |
Risk factors of preterm birth......................................................70 |
Robotic myomectomy..............................................................211 |
Salpingectomy.............................................................................47 |
Salpingo-oophorectomy.............................................................47 |
Sarcoma...............................................................................15, 154 |
Selective fetal reduction.............................................................79 |
Single twin demise...................................................................147 |
Sperm parameters........................................................................1 |
St. John’s wort.............................................................................65 |
Stacked ensemble......................................................................70 |
Stacked generalization...............................................................70 |
Stage...........................................................................................224 |
Stillbirth......................................................................................106 |
Stress..........................................................................................218 |
Surgical findings........................................................................133 |
Survival.................................................................31, 154, 213, 224 |
Symptoms..................................................................................178 |
Technique..................................................................................272 |
Total abdominal hysterectomy................................................142 |
Total laparoscopic hysterectomy............................................142 |
Transobturator...........................................................................243 |
Treatment modalities...............................................................196 |
Twin pregnancy.........................................................................147 |
Umbilical ligament......................................................................62 |
Unfavorable cervix....................................................................231 |
Uterine..........................................................................................15 |
Uterine leiomyoma.....................................................................23 |
Uteroplacental insufficiency....................................................106 |
Vaginal hysterectomy....................................................................8 |